Biotechnology

Spero Therap

Spero Therap released FY2026 Q1 earnings on May 13 After-Market (EST), actual revenue USD 258K, actual EPS USD -0.1257 (forecast EPS USD -0.18)

Spero Therap to Release FY2026 Q1 Earnings on May 13 After-Market (EST), Forecast EPS -0.18 USD

Spero Therap released FY2025 Annual Earnings on March 26 After-Market (EST), Actual Revenue: USD 66.8 M (Forecast: USD 25.5 M), Actual EPS: USD 0.15 (Forecast: USD -0.1)

Spero Therap released FY2025 Q4 earnings on March 26 After-Market EST, actual revenue USD 41.3 M (forecast USD 0), actual EPS USD 0.5357 (forecast USD -0.2)

Spero Therapeutics to Release FY2025 Q4 Earnings on March 26, 2026 After-Market EST, Forecast Revenue USD 0, EPS USD -0.2

Spero Therapeutics Partner GSK Resubmits tebipenem HBr NDA to FDA

Spero Therap released FY2025 9 Months earnings on November 13 After-Market (EST), actual revenue USD 25.51 M, actual EPS USD -0.4119

Spero Therap released FY2025 Q3 earnings on November 13 After-Market EST, with actual revenue of USD 5.442 M (forecast USD 0) and actual EPS of USD -0.1311 (forecast USD -0.25)

Spero Therapeutics to Release FY2025 Q3 Earnings on November 13 After-Market (EST), Forecast EPS -0.25 USD

Spero Therapeutics and GSK Announce Positive Results for tebipenem HBr Phase III Trial

Spero Therap released FY2025 Semi-Annual Earnings on August 12 After-Market (EST), Actual Revenue: USD 20.06M, Actual EPS: USD -0.2794

Spero Therap released FY2025 Q2 earnings on August 12 After-Market EST: Actual Revenue USD 14.19 M (Forecast USD 0), Actual EPS USD -0.0303 (Forecast USD -0.38)

Spero Therap to Release FY2025 Q2 Earnings on August 12 After-Market EST, Forecast EPS USD -0.38

Spero Therapeutics Inc. Holds Annual General Meeting

Spero Therapeutics and GSK's tebipenem HBr Achieves Success in cUTI Trial

Spero Therap released FY2025 Q1 earnings on May 13 After-Market EST, actual revenue USD 5.874 M (forecast USD 0), actual EPS USD -0.2503 (forecast USD -0.55)

Spero Therapeutics Reports Quarterly Earnings

Spero Therapeutics Inc Expected to Report a 55-Cent Loss Per Share

Spero Therap to Release FY2025 Q1 Earnings on May 13 After-Market EST, Forecast EPS USD -0.55

Spero Therapeutics Appoints Esther Rajavelu as President and CEO

Aditxt

LINKERS INDUSTRIES LIMITED

Freecast

Butterfly Network

CDT Equity

Asia Pacific Wire & Cable

Agape ATP

Bimergen Energy

Horizon Quantum

Defiance Daily Target 2X Long VELO ETF

LNAI

NVCR

SPRO

ADTX

In Thursday's pre-market session, several healthcare stocks saw significant movement. Aditxt surged 247.7% to $0.02, while CervoMed rose 25.72% to $4.79. Other gainers included QTREX Quantum, Butterfly Network, Spero Therapeutics, and Agape ATP. Conversely, Profusa dropped 31.0% to $0.18, NewGenIvf fell 22.33% to $0.62, and Elicio Therapeutics declined 20.73% to $3.73. Losers also included Ernexa Therapeutics, NovoCure, and Lunai Bioworks.

benzinga_article

Lunai Bioworks

Novocure

Profusa

NewGenIvf

CervoMed

Ernexa Therapeutics

QTREX Quantum

Elicio Therapeutics

BUTTERFLY NETWORK INC C/WTS 12/02/2026 (TO PUR COM)

PROFUSA INC. C/WTS 02/08/2027 (TO PUR COM)

NEWGENIVF GROUP LIMITED C/WTS 03/04/2029(TO PUR COM)

12 Health Care Stocks Moving In Thursday's Pre-Market Session

RUMBW

SWBI

Stock futures rose modestly as the Fed signaled potential year-end rate hikes. Key movers included Rumble (+17%) after acquiring Northern Data AG, Smith & Wesson (+14%) on strong Q4 results, Spero Therapeutics (+11%) following FDA approval of Utebzi, and Intel (+9%) due to Trump's announcement of Apple chip production in the US. Conversely, Legend Biotech (-8%) fell after pricing a $226M equity offering, and Steel Dynamics (-3%) dropped on lowered Q2 earnings guidance.

- Stock futures saw a modest increase in early trading on Thursday after the Federal Reserve suggested potential interest rate hikes before the year ends.  
- Notable stock movements included Rumble (RUM), which surged by 17% following the announcement of a new business unit and legal name change.  
- These developments indicate a response to shifting monetary policy and company-specific strategies.

Rumble

RUMBLE INC C/WTS 16/09/2027 (TO PUR COM)

Steel Dynamics

Smith & Wesson Brands

Northern Data AG

Intel

INTEL-T

Legend Biotech

GraniteShares 2x Long INTC Daily ETF

Direxion Daily INTC Bull 2X ETF

YieldMax INTC Option Income Strategy ETF

Biggest stock movers Thursday: INTC, RUM, SPRO and more

Smith & Wesson Brands (SWBI) reported Q4 earnings that significantly beat analyst estimates, with EPS of $0.36 versus $0.23 expected and revenue of $178.39 million against $155.27 million projected. CEO Mark Smith highlighted strong execution across revenue, profitability, cash flow, and debt reduction. Following the report, SWBI stock surged 14.71% to $15.75 in extended trading.

Palantir Tech

Smith & Wesson Stock Shoots Higher After Q4 Earnings — Here's Why

Spero Therap rose 27.49% in after-hours trading; Elicio Therapeutics fell 15.07% in after-hours trading, with a trading volume of USD 445,300; Moderna rose 0.50% in after-hours trading, with a trading volume of USD 438,700; BeiGene rose 2.94% in after-hours trading, with a trading volume of USD 222,200

Price Alert

Moderna

Beigene

U.S. stock night market volatility: Spero surged 27.49% in after-hours trading! Oral antibiotics approved, GSK backing ignites funding

The FDA has approved Utebzi (tebipenem pivoxil hydrobromide), the first oral carbapenem antibiotic for complicated urinary tract infections, developed by GSK and Spero Therapeutics. This approval addresses a significant unmet need in treating multidrug-resistant pathogens. The launch is scheduled for late 2026. Following the announcement, GSK shares rose 0.64%, while Spero Therapeutics shares fell 18.41%.

GlaxoSmithKline plc

Nuvalent

Snap

GSK plc Sponsored ADR

GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs

QURE

RGNT

ICCM

During Wednesday's intraday session, several healthcare stocks experienced significant volatility. Gainers included Icecure Medical (up 290.6%), uniQure (up 74.84%), and Lunai Bioworks (up 57.99%). Conversely, major losers featured Aditxt (down 42.2%), Regentis Biomaterials (down 20.01%), and Spero Therapeutics (down 18.24%). The report highlights substantial price movements across various market capitalizations in the healthcare sector.

Uniqure

Regentis Biomaterials

Icecure Medical

ClearPoint Neuro

Stablecoin Development

Co-Diagnostics

IM Cannabis

12 Health Care Stocks Moving In Wednesday's Intraday Session

The FDA has approved Utebzi (tebipenem pivoxil), the first and only oral carbapenem antibiotic, for treating complicated urinary tract infections in adults. Developed by Spero Therapeutics and licensed to GSK, this approval follows the PIVOT-PO trial demonstrating non-inferiority to intravenous treatment. It aims to reduce hospital reliance and address resistant infections, with availability expected by late 2026.

StockTitan

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) | SPRO Stock News

Spero Therap(SPRO.US)